A drug trial gone wrong has left a 20-year-old London man with the prospect of losing all his fingers and toes.
Trainee plumber Ryan Wilson developed gangrene in both his hands and feet after taking part last March in the test of an arthritis drug developed by TeGenero for U.S. researchers Parexel, Britain's Daily Mirror reported Monday.
Six men had multiple organ failure after testing the drug but an official investigation into the trial found no evidence of problems. The drug caused volunteer's heads to swell like the Elephant Man.
Wilson expected to lose just a few finger tips but at his last checkup doctors told him to prepare for amputation in a month.
His family does not know how long it will be before he can walk again.
Copyright 2006 by United Press International
Related stories:
Research finds drug candidate slows age-related macular degeneration
Research results from the Case Western Reserve University School of Medicine show that the progression of age-related macular degeneration (AMD) is markedly slowed in new laboratory-engineered mice when they received treatments of retinylamine, a trial drug that has been tested in a medical school lab. AMD is a leading cause of vision loss in Americans 60 years of age and older.
Tamoxifen chemoprevention tied to early detection of breast cancer
The drug tamoxifen does not prevent or treat estrogen receptor (ER) negative breast cancer, but it can make the disease easier to find, researchers report in the Oct. 1
Journal of the National Cancer Institute.
Researchers propose minocycline as a promising drug for patients with Fragile X syndrome
A UC Riverside-led team of biomedical scientists has found that a readily available drug called minocycline, used widely to treat acne and skin infections, can be used to treat
Fragile X syndrome, the most common inherited cause of mental impairment and the most common cause of autism.
Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results
Engineers at the Georgia Institute of Technology have developed a prosthetic vein valve to help improve the lives of those suffering from a condition known as chronic venous insufficiency. The condition, which affects more than seven million people in the United States alone, occurs when valves in a person's veins can no longer ensure a one-way flow of blood back to the heart.
Gene therapy for chronic pain gets first test in people
This week, University of Michigan scientists will begin a phase 1 clinical trial for the treatment of cancer-related pain, using a novel gene transfer vector injected into the skin to deliver a pain-relieving gene to the nervous system.
Deep brain stimulation offers hope to people with treatment-resistant illnesses
Every day during a four-year deep depression, Sean Miller thought of ending his life. Nothing relieved the emotional darkness - not therapy, not medication, not loving attention from family and friends.
As head and neck cancer risks evolve, more treatment options emerge
Advances in understanding head and neck cancer over the last decade have led to more treatment options and improved quality of life for patients, according to a review published this week in the
New England Journal of Medicine.
Got Gout? Duke Leads Study of New Treatment
(PhysOrg.com) -- A new drug designed to normalize levels of uric acid in the blood appears to be safe and tolerable and may help patients with the painful arthritic condition known as gout better cope with their disease, say researchers at Duke University Medical Center.